ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0104

Cluster Analysis of Antiphospholipid Antibodies Associated Adverse Pregnancy Outcome Patients: Based on a 13-year Longitudinal Cohort Study

Yin Long1, Jiuliang zhao2, Mengtao Li2, Xinping Tian2 and xiaofeng Zeng3, 1Peking Union Medical College Hospital Department of Rheumatology and Clinical Immunology, Beijing, China, 2Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 3Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

Meeting: ACR Convergence 2023

Keywords: antiphospholipid syndrome, autoantigens, longitudinal studies, pregnancy, Women's health

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0096–0116) Antiphospholipid Syndrome Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Antiphospholipid antibodies (aPLs) play a pivotal role in the etiology of adverse pregnancy outcomes (APOs). (1) Women with persistently aPLs positivity present heterogeneous clinical manifestations and APOs. We aimed to stratify aPLs positivity patients with APOs and assess the subsequent pregnancy outcomes.

Methods: This was a retrospective study of persistent aPLs positive women cohort in Peking Union Medical College Hospital. Baseline demographic characteristics, clinical manifestation, previous APOs and antibodies profiles were analyzed. Placentae from patients were collected and performed the histopathologic diagnoses during the follow up.

Results: Four clusters among 209 patients with 477 pregnancies were identified. Cluster 1 comprised patients with triple aPLs positivity and demonstrates a high incidence of gestational hypertension (34.92%, P = 0.008) and preterm delivery (20.63%, P = 0.021). Patients in cluster 2 were characterized by lupus anticoagulant (LA) positivity, with high risk of whole gestational APOs. Cluster 3 included patients with isolated aPLs-IgM isotype combined with early miscarriage (60.92%, P = 0.01). Patients in cluster 4 majorly presented aPLs-IgG isotype combined with placenta insufficiency (22.73%, P = 0.016). During the follow up, the live birth rate in cluster 1 and 2 was only 69.20%. Gestational hypertension was much higher in cluster 1 (15.4%, P = 0.05). Placenta pathology revealed that the patient in cluster 1 exhibited a conspicuous reduction in the number of capillaries present within the placental villi, coupled with hypoplastic chorionic capillaries. The representative placental pathology of the cluster 3 likewise showed a reduced number of stem villi capillaries and slight swelling and degeneration of the endothelium in the stem villi vessels. Placenta in cluster 4 had mildest placental lesions.

Conclusion: In conclusion, our study identified four clusters of patients with aPLs-associated APO. There exists a correlation between specific aPLs isotypes and the occurrence of adverse pregnancy events at different stages of gestation. Triple aPLs positivity is associated with gestational hypertension and preterm delivery. LA positivity is a significant risk factor for the whole gestational APOs. While patients with isolated aPLs-IgM isotype are more likely to have early miscarriage. Patients in cluster 4 majorly present aPLs-IgG isotype combined with placenta insufficiency. The four identified clusters based on clinical and laboratory features showed distinct differences in pregnancy outcomes and placental damage. These findings suggest that an individualized risk stratification approach to the management of persistent aPLs positive women may improve pregnancy outcomes, taking into consideration the clinical phenotype and placental pathology.

1. Branch DW, Silver RM, Blackwell JL, et al. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstetrics and gynecology. 1992;80(4):614-20

Supporting image 1

Figure 1. Study flowchart and cluster analysis; A. Study flowchart; B. Cluster analysis

Supporting image 2

Figure 2. Representative placentae HE of four clusters.

Supporting image 3

Table 1. Comparison of baseline pregnancy outcomes and antibodies between four clusters;
Table 2. Newly pregnancy outcomes in four clusters;
Table 3. Comparison of pregnancy outcomes before and after enrollment.


Disclosures: Y. Long: None; J. zhao: None; M. Li: None; X. Tian: None; x. Zeng: None.

To cite this abstract in AMA style:

Long Y, zhao J, Li M, Tian X, Zeng x. Cluster Analysis of Antiphospholipid Antibodies Associated Adverse Pregnancy Outcome Patients: Based on a 13-year Longitudinal Cohort Study [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/cluster-analysis-of-antiphospholipid-antibodies-associated-adverse-pregnancy-outcome-patients-based-on-a-13-year-longitudinal-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cluster-analysis-of-antiphospholipid-antibodies-associated-adverse-pregnancy-outcome-patients-based-on-a-13-year-longitudinal-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology